MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan
through our joint development with MediciNova, we will proceed with further non-clinical and clinical trial development as quickly as possible globally and not only in Japan.
We are confident that the BC-PIV SARS-CoV-2 vaccine will be successful and hope that this vaccine will be available in a clinical setting as soon as possible and will be the “gospel” for the people in the world.”
globenewswire.com/news-release/2020/07/27/2067757/0/en/MediciNova-Announces-SARS-CoV-2-Vaccine-Joint-Development-with-BioComo-and-Mie-University-Japan.html
fool.com/investing/2020/07/27/heres-why-medicinova-is-soaring-today.aspx
through our joint development with MediciNova, we will proceed with further non-clinical and clinical trial development as quickly as possible globally and not only in Japan.
We are confident that the BC-PIV SARS-CoV-2 vaccine will be successful and hope that this vaccine will be available in a clinical setting as soon as possible and will be the “gospel” for the people in the world.”
globenewswire.com/news-release/2020/07/27/2067757/0/en/MediciNova-Announces-SARS-CoV-2-Vaccine-Joint-Development-with-BioComo-and-Mie-University-Japan.html
fool.com/investing/2020/07/27/heres-why-medicinova-is-soaring-today.aspx
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。